<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02598219</url>
  </required_header>
  <id_info>
    <org_study_id>SENTIRAD-1502</org_study_id>
    <nct_id>NCT02598219</nct_id>
  </id_info>
  <brief_title>Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.</brief_title>
  <acronym>SENTIRAD</acronym>
  <official_title>Randomized Study Comparing Sentinel Node (SN) Policy to Current French Initial Staging Protocols in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canceropôle Nord Ouest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the sentinel node policy in early stage endometrial
      carcinomas at intermediate and high risk of recurrence (by comparing the sentinel node policy
      to current French initial staging protocols).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Routine exams required for diagnosis:

             -  Endometrioid biopsy or product of a dilatation-curettage under hysteroscopy for
                diagnosis of histologic typing

             -  Tumor assessment: Lombopelvic MRI (1.5 or 3T) with gadolinium injection, studied by
                steady and dynamic sequences. US and CT-Scan in case of intolerance to MRI should
                be discussed. FDG-PET may be an option.

        2. Tumor board: The completed chart will be reviewed to confirm the risk group and
           indication.

        3. Complete physical and gynecological examination by surgical oncologist followed by a
           consultation of anesthesiology to confirm the operability of patient.

        4. Informed and signed consent form.

        5. Study baseline assessment.

           Then,

        6. Randomization before surgery that should be performed according to the arm within a
           maximum of 4 weeks from the first consultation.

           Arm A: Sentinel node policy*

           Arm B:

             -  Bilateral pelvic lymphadenectomy (intermediate risk endometrioid)

             -  Or Ilio-infrarenal paraaortic lymphadenectomy (high risk endometrioid)

             -  Or Pelvic + paraaortic lymphadenectomies (high risk non endometrioid)*

                  -  along with a peritoneal staging for each arm (cytology, random biopsies,
                     infracolic omentectomy)

        7. Second tumor board: after definitive pathological results of the
           hysterectomy-annexectomy and node (sentinel or not) specimens.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Specific intra operative morbidity</measure>
    <time_frame>During surgery</time_frame>
    <description>Intra operative morbidity will be evaluated according to the &quot;Oslo&quot; classification.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of detected sentinel node</measure>
    <time_frame>During surgery</time_frame>
    <description>number of patients with ≥ 1 Sentinel Node (SN) / total number of explored patients, and bilaterality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of pN1</measure>
    <time_frame>an average of 1 month after surgery</time_frame>
    <description>n pN1 / total N</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>Up to 5 years after surgery</time_frame>
    <description>Time from the date of randomization to the first documentation of local, regional or distant disease or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years after surgery</time_frame>
    <description>Time from the date of randomization to the date of death (indicate if the death is due to disease progression or not).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific post operative morbidity</measure>
    <time_frame>Up to 30 days after the surgery</time_frame>
    <description>Post-operative morbidity will be evaluated according to Clavien Dindo 2009 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant complications</measure>
    <time_frame>After 30 days post-surgery and up to 5 years</time_frame>
    <description>Distant complications will be evaluated according to NCI-CTCAE v4.03 scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Endometrial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Pre-operative SN mapping with Nanocis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 'Pre-operative Sentinel Node (SN) mapping with Nanocis'
2- Intra-operative SN mapping with patent V blue dye, or Intra-operative SN mapping with indocyanin green for patients with known hypersensitivity, allergy to patent V blue dye
3- Full bilateral laparoscopic lymphadenectomy and Hysterectomy: If bilateral SN are detected, all positive SN are removed, then the surgeon proceeds to a total hysterectomy. If non SN are detected, or only unilateral SN are detected, the surgeon will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral lymphadenectomy with more enlarged dissection regardless the pathology.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B : Current initial staging protocols</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Current French initial staging protocols</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pre-operative SN mapping with Nanocis</intervention_name>
    <description>Preparation : four 1ml syringe are prepared per patient, each containing a total activity 10 MBq if the injection is planned the same day of surgery and in the operative theater OR each containing a total activity 30MBq if the injection is performed the day before the surgery.
Intracervical injection is performed by the surgeon, no more than 3-24 hours before surgery : 4 submucous injections with the filtered radiocolloid at 3, 6, 9 and 12 o'clock positions. Each injection if performed at 2 mm of depth for a total activity of 40 MBq or a total activity of 120 MBq is the surgery is planned the day after the injection.
Sentinel Node detection by planar scintigraphy at 1 and 3h (if no detection at 1 hour), or by SPECT-CT imaging if available.</description>
    <arm_group_label>Pre-operative SN mapping with Nanocis</arm_group_label>
    <other_name>Pre-operative Sentinel Node</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intra-operative SN mapping with patent V blue dye</intervention_name>
    <description>Patent blue V dye are diluted with saline sterile solution to obtain 4ml of 50%. Four 1ml syringe, each containing a 50% patent blue dye solution, are prepared per patient.
Intracervical injection is performed by the surgeon. after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible.
SN are detected by direct visualization of blue colored lymphatics and node</description>
    <arm_group_label>Pre-operative SN mapping with Nanocis</arm_group_label>
    <other_name>Intra-operative SN mapping</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intra-operative SN mapping with indocyanin green</intervention_name>
    <description>1: Infracyanine powder is diluted in aqueous sterile water to obtain 4ml with a concentration of 1.25 mg/mL. Four 1ml syringe, each containing a 1.25 mg/mL Infracyanine dye solution, are prepared per patient.
2- Intracervical injection is performed by the surgeon, after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible
3- SN detection by near-infrared fluorescence imaging</description>
    <arm_group_label>Pre-operative SN mapping with Nanocis</arm_group_label>
    <other_name>Intra-operative Sentinel Node (SN) mapping with Infracyanine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Full bilateral laparoscopic lymphadenectomy and Hysterectomy</intervention_name>
    <description>Bilateral pelvic lymphadenectomy (intermediate risk endometrioid)
Or Ilio-infrarenal paraaortic lymphadenectomy (high risk endometrioid)
Or Pelvic + paraaortic lymphadenectomies (high risk non endometrioid)</description>
    <arm_group_label>Pre-operative SN mapping with Nanocis</arm_group_label>
    <other_name>Full bilateral lymphadenectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Current initial staging protocols</intervention_name>
    <description>Current French initial staging protocols</description>
    <arm_group_label>B : Current initial staging protocols</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with early endometrial carcinoma with early FIGO clinical stage I-II
             (clinical examination, abdomino-pelvic MRI/Ultrasound - or CT scan if MRI not possible
             - and endometrial biopsy or curettage), then stratification of the recurrence risk as
             defined by European Society for Medical Oncology (ESMO):

               -  Intermediate-risk endometrioid (type 1): 2009 FIGO stage IA/T1a grade 3, or IB-II
                  grade 1 or 2

               -  Or High risk endometrioid (type 1) : 2009 FIGO stage IB/T1b or II, grade 3

               -  Or High risk non endometrioid (type 2) : 2009 FIGO stages I-II

          2. Without any suspicious pelvic, paraaortic, distant node at preoperative MRI

          3. Age ≥ 18 years

          4. Performance status (OMS) ≤ 2

          5. No contraindication to surgery

          6. Absence of known hypersensitivity to colloidal rhenium sulphide and technetium
             (nanocolloid) or one of its excipients, to injectable dyes (blue dye or indocyanine
             green if available) or one of their excipients, to triphenylmethane derivatives

          7. Signed and dated informed consent

          8. Effective contraception for patients with reproductive potential

          9. Patient affiliated with a health insurance system

        Exclusion Criteria:

          1. Preoperative workup with :

               -  Previous hysterectomy (by nature, this trial cannot be offered as a secondary
                  staging procedure)

               -  non carcinoma (for example sarcoma, trophoblastic tumor)

               -  Low-risk endometrioid carcinoma as defined by the ESMO: 2009 FIGO stage IA grade
                  1-2

               -  Metastatic disease

               -  Suspicious adenopathy at preoperative workup

          2. Pregnant and/or breastfeeding woman

          3. No comprehension of the trial

          4. Patient deprived of liberty or in guardianship

          5. Inexperience in pelvic sentinel node detection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric LEBLANC, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hélène GAUTHIER, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alicia PROBST</last_name>
    <email>a-probst@o-lambret.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rajeev RAMANAH, MD, PhD</last_name>
      <email>rajeev.ramanah@univ-fcomte.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric GUYON, MD</last_name>
      <email>f.guyon@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe POMEL, MD</last_name>
      <email>christophe.pomel@cjp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric LEBLANC, MD</last_name>
      <email>e-leblanc@o-lambret.fr</email>
    </contact>
    <contact_backup>
      <last_name>Hélène GAUTHIER, MD</last_name>
      <email>h-gauthier@o-lambret.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital Jeanne de Flandres, CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre COLLINET, MD</last_name>
      <email>pierre.collinet@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Mère-Enfant, CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tristan GAUTHIER, MD</last_name>
      <email>tristan.gauthier@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric BEURRIER, MD</last_name>
      <email>frederic.beurrier@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric LAMBAUDIE, MD</last_name>
      <email>lambaudiee@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne MOURREGOT, MD</last_name>
      <email>Anne.Mourregot@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest, René Gauducheau</name>
      <address>
        <city>Nantes Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Marc CLASSE, MD, PhD</last_name>
      <email>jean-marc.classe@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital La Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérémie BELGHITI, MD</last_name>
      <email>jeremie.belghiti@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice LECURU, MD, PhD</last_name>
      <email>fabrice.lecuru@egp.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emile DARAI, MD, PhD</last_name>
      <email>emile.darai@tnn.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vvien CECCATO, MD</last_name>
      <email>vivien.ceccato@reims.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier GRAESSLIN, MD, PhD</last_name>
      <email>ograesslin@chu-reims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David HAMID, MD</last_name>
      <email>dhamid@strasbourg.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Jacques BALDAUF, MD, PhD</last_name>
      <email>Jean-Jacques.Baldauf@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwénaël FERRON, MD</last_name>
      <email>ferron.gwenaël@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2015</study_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sentinel node</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

